Covid-19: Updated Guidance on Vaccines, Masks, and… Mammograms?
Public health organizations release new recommendations as pandemic rages on The CDC and other...
Breast Cancer Oncology
Empathy, The Best Medicine? How Doctors can Help Patients Remember More Information and Make Better-Informed Decisions
The expression “It shouldn’t have to happen to you to matter to you” has been making the rounds on...
Eribulin with/without Pembrolizumab for Metastatic Breast Cancer
In women with metastatic breast cancer, programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors are given as the primary line of monotherapy. However, in patients with hormone receptor-positive...
Pembrolizumab Plus Neoadjuvant Chemotherapy for Early-Stage Breast Cancer
Neoadjuvant chemotherapy is routinely assigned to women with early-stage breast cancer, but approximately 25% of them experience a recurrence within 5 years. Combining pembrolizumab, a humanized antibody, with neoadjuvant...
Breastfeeding and Ovarian Cancer Risk
Several studies have been conducted to investigate the association between breastfeeding and ovarian cancer; some show a positive association, and some show no association at all. This study aims to determine the exact...
Breast Cancer Risk in Transgender People Receiving Hormone Treatment
Transgender people undergo prolonged hormone treatment, which may be associated with an increased risk of breast cancer. This study aims to evaluate the incidence of breast cancer in trans men and women who received...
ASCO: Virtual Meeting Kicks Off May 29
Three days packed with presentations The American Society of Clinical Oncology is the leading oncology research meeting worldwide, but just like other medical conferences, ASCO 2020 was forced to make many changes to deliver on...
AACR 2020: Tumor Immune Biology Differs Between Metastatic & Early TNBC
Although research has linked pre-existing intratumoral immune response—characterized by presence of tumor-infiltrating lymphocytes or cytotoxic effector T cells—with improve prognosis in early triple-negative breast cancer...
AACR 2020: Pre-existing ESR1 Mutations Predict Endocrine Therapy Failure & Poor Survival
Despite research suggesting that mutation in ESR1 is an acquired mechanism of resistance to endocrine therapy (ET), the impact of this mutation on therapy response in primary breast cancer remains unclear. To better understand...
FDA Approves Sacituzumab Govitecan for Metastatic, Triple-Negative Breast Cancer
New Tx available to patients who have tried two prior treatments WASHINGTON — Sacituzumab govitecan-hziy (Trodelvy) is now FDA-approved to treat adults with metastatic triple-negative breast cancer.The drug — which...
CLEOPATRA Closes Landmark Survival Analysis in HER2-Positive Metastatic Breast Cancer
More than 33% of women treated with dual HER2 blockade plus docetaxel were still alive 8 years after Dx Previously reported improvements in overall survival (OS) with dual HER2 receptor blockade plus docetaxel in HER2-positive...
At-Home Tool Helps Older Women Understand Breast Ca Screening Options
Benefits and harms clarified with decision aid in women ages 75-plus Older women who received a decision aid on screening mammography before seeing their primary care physician (PCP) were less likely to choose screening,...
